| 1 |
34694880 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults. | 2022 Jan 18 |
1 |
| 2 |
35507130 | Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations. | 2022 May 4 |
1 |
| 3 |
32962959 | Exploring redox vulnerabilities in JAK2V617F-positive cellular models. | 2021 Oct-Dec |
2 |
| 4 |
33052714 | Targeting Jak-Stat Signaling in Experimental Pulmonary Hypertension. | 2021 Jan |
1 |
| 5 |
33465556 | Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3. | 2021 Feb |
1 |
| 6 |
33517393 | Mosaic IL6ST variant inducing constitutive GP130 cytokine receptor signaling as a cause of neonatal onset immunodeficiency with autoinflammation and dysmorphy. | 2021 Apr 26 |
2 |
| 7 |
33548083 | Downregulation of SHANK-associated RH domain-interacting protein elevates interleukin-33 expression by stimulating the Janus kinase 2/signal transducer and activator of transcription signalling pathway in HaCaT cells. | 2021 Jul |
1 |
| 8 |
33662027 | Differential responses to folic acid in an established keloid fibroblast cell line are mediated by JAK1/2 and STAT3. | 2021 |
1 |
| 9 |
34396051 | AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms. | 2021 Sep |
1 |
| 10 |
31452174 | Inhibition of the Invasion of Human Glioblastoma U87 Cell Line by Ruxolitinib: A Molecular Player of miR-17 and miR-20a Regulating JAK/STAT Pathway. | 2020 |
2 |
| 11 |
31837586 | Cellular cytokine receptor signaling and ATM pathway intersections affect hepatic DNA repair. | 2020 Mar |
1 |
| 12 |
32022429 | LPS-induced inflammation desensitizes hepatocytes to Fas-induced apoptosis through Stat3 activation-The effect can be reversed by ruxolitinib. | 2020 Mar |
2 |
| 13 |
32047890 | Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. | 2020 Mar 26 |
1 |
| 14 |
32234672 | Janus kinase-dependent regulation of drug detoxifying protein expression by interleukin-22 in human hepatic cells. | 2020 Jun |
1 |
| 15 |
32330554 | Overexpression of LINC00691 promotes the proliferation and invasion of gastric cancer cells via the Janus kinase/signal transducer and activator of transcription signalling pathway. | 2020 Jun |
1 |
| 16 |
32758351 | Signal transducer and activator of transcription (STAT) 1 and STAT3 are expressed in the human ovary and have Janus kinase 1-independent functions in the COV434 human granulosa cell line. | 2020 Aug |
1 |
| 17 |
32844992 | The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. | 2020 Nov 12 |
1 |
| 18 |
32944850 | Ruxolitinib Controls Lymphoproliferation and Diabetes in a STAT3-GOF Patient. | 2020 Nov |
1 |
| 19 |
33490193 | Inhibition of IL-6/JAK/STAT3 pathway rescues denervation-induced skeletal muscle atrophy. | 2020 Dec |
2 |
| 20 |
30557559 | Efficacy of Ruxolitinib Therapy in a Patient With Severe Enterocolitis Associated With a STAT3 Gain-of-Function Mutation. | 2019 Mar |
1 |
| 21 |
30930994 | Inhibition of tumor growth and angiogenesis of tamoxifen-resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor. | 2019 Apr |
1 |
| 22 |
31147469 | JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors. | 2019 Jun 18 |
1 |
| 23 |
31182137 | AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway. | 2019 Jun 10 |
1 |
| 24 |
30123428 | STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target. | 2018 Jul 24 |
2 |
| 25 |
30340199 | A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. | 2018 Nov |
1 |
| 26 |
28053127 | Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer. | 2017 Apr |
1 |
| 27 |
28463395 | Clinical relevance of circulating anti-ENA and anti-dsDNA secreting cells from SLE patients and their dependence on STAT-3 activation. | 2017 Jul |
2 |
| 28 |
28684419 | Versican G1 domain enhances adenoviral-mediated transgene expression and can be modulated by inhibitors of the Janus kinase (JAK)/STAT and Src family kinase pathways. | 2017 Sep 1 |
1 |
| 29 |
28722170 | Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells. | 2017 Nov 15 |
1 |
| 30 |
28784136 | Secretory RAB GTPase 3C modulates IL6-STAT3 pathway to promote colon cancer metastasis and is associated with poor prognosis. | 2017 Aug 7 |
2 |
| 31 |
29228628 | Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. | 2017 Nov 14 |
1 |
| 32 |
26701727 | Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma. | 2016 Feb 2 |
1 |
| 33 |
26811457 | Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma. | 2016 Feb 9 |
1 |
| 34 |
26981780 | Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS. | 2016 Apr 5 |
1 |
| 35 |
27123832 | Identification of TBK1 and IKKε, the non-canonical IκB kinases, as crucial pro-survival factors in HTLV-1-transformed T lymphocytes. | 2016 Jul |
1 |
| 36 |
27379204 | Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic. | 2016 |
1 |
| 37 |
27474009 | Fibroblast activation in cancer: when seed fertilizes soil. | 2016 Sep |
1 |
| 38 |
27579615 | Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. | 2016 Nov 8 |
1 |
| 39 |
25749974 | Aberrant cytokine production by nonmalignant cells in the pathogenesis of myeloproliferative tumors and response to JAK inhibitor therapies. | 2015 Mar |
1 |
| 40 |
26356819 | Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells. | 2015 Oct 6 |
1 |
| 41 |
24497534 | GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. | 2014 May 8 |
1 |
| 42 |
24778152 | Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. | 2014 Jun 12 |
1 |
| 43 |
25213670 | Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC. | 2014 Nov |
2 |